Acute myeloid leukemia in the older patient.

[1]  D. Gilliland,et al.  Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.

[2]  M. Mancini,et al.  Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype , 2002, Leukemia.

[3]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden , 2002, Cancer.

[4]  M. Lichtman.  The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective , 2001, Leukemia.

[5]  R. Clark,et al.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[6]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.

[7]  J. Radich,et al.  FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. , 2001, Blood.

[8]  R. Golub,et al.  Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial , 2001, Cancer investigation.

[9]  J. Armitage,et al.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Neubauer,et al.  Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions , 2000, Leukemia.

[11]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[12]  R. Golub,et al.  Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Harousseau.  Acute myeloid leukemia in the elderly. , 1998, Blood reviews.

[14]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[15]  P. Hurteloup,et al.  A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients , 1998 .

[16]  A. Ganser,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia , 1997 .

[17]  M A Boogaerts,et al.  Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. McCulloch.  Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J. Bennett,et al.  Long‐term survival in acute myeloid leukemia , 1997, Cancer.

[20]  T. Naoe,et al.  Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines , 1997, Leukemia.

[21]  T. Naoe,et al.  Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia , 1997, Leukemia.

[22]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[23]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[24]  J. A. Tisone,et al.  Acute Myeloblastic Leukemia , 1996 .

[25]  C. Schiffer.  Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. , 1996, Blood.

[26]  D. Head,et al.  Revised classification of acute myeloid leukemia. , 1996, Leukemia.

[27]  F. Mandelli,et al.  Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Chatta,et al.  Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. , 1996, Blood.

[29]  R. Geller,et al.  Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Paietta,et al.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.

[31]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[32]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[33]  L. Weng,et al.  Identification of growth factor-responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation. , 1994, Leukemia.

[34]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[35]  Masahiro Yoshida,et al.  A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments] , 1994 .

[36]  W. Hiddemann,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. , 1991, Blood.

[37]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[38]  M. Andreeff,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. , 1991, Blood.

[39]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[40]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[41]  K. Bhalla,et al.  Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. , 1988, Leukemia.

[42]  J. Rowley,et al.  Associations between morphology, karyotype, and clinical features in myeloid leukemias. , 1987, Human pathology.

[43]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[44]  D. Catovsky,et al.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[45]  J. Rowley.  CHROMOSOME CHANGES IN ACUTE LEUKAEMIA , 1980, British journal of haematology.

[46]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[47]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.

[48]  J. Dick,et al.  Distinct classes of human stem cells that differ in proliferative and self-renewal potential , 2001, Nature Immunology.

[49]  I. Bernstein,et al.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. , 2001, Blood.

[50]  J. Spivak,et al.  Commentary on and reprint of Till JE, McCulloch EA, A direct measurement of the radiosensitivity of normal mouse bone marrow cells, in Radiation Research (1961) 14:213–222 , 2000 .

[51]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[52]  D. Birnbaum,et al.  Hematopoietic receptors of class III receptor-type tyrosine kinases. , 1993, Critical reviews in oncogenesis.